期刊簡介 | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | Canadian Journal of Diabetes LetPub Score 6.2
50 ratings
Rate
Reputation 7.5 Influence 4.9 Speed 7.0 | ||||||||||||||||||||||||
期刊簡稱 | CAN J DIABETES | ||||||||||||||||||||||||
ISSN | 1499-2671 | ||||||||||||||||||||||||
E-ISSN | 2352-3840 | ||||||||||||||||||||||||
h-index | 31 | ||||||||||||||||||||||||
CiteScore |
| ||||||||||||||||||||||||
自引率 (2023-2024) | 8.70%自引率趨勢 | ||||||||||||||||||||||||
掲載範囲 |
| ||||||||||||||||||||||||
官方網站 | http://www.canadianjournalofdiabetes.com/ | ||||||||||||||||||||||||
在線稿件提交 | https://www.editorialmanager.com/CJD | ||||||||||||||||||||||||
開放訪問 | No | ||||||||||||||||||||||||
出版商 | Elsevier Inc. | ||||||||||||||||||||||||
主題領域 | ENDOCRINOLOGY & METABOLISM | ||||||||||||||||||||||||
出版國/地區 | CANADA | ||||||||||||||||||||||||
發行頻率 | 四半期刊行 | ||||||||||||||||||||||||
創刊年 | 2002 | ||||||||||||||||||||||||
每年文章數 | 81每年文章數趨勢 | ||||||||||||||||||||||||
黃金OA百分比 | 11.15% | ||||||||||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q3
| ||||||||||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1499-2671%5BISSN%5D | ||||||||||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: | ||||||||||||||||||||||||
競爭力 * | 來自作者的數據: Easy | ||||||||||||||||||||||||
參考鏈接 |
| ||||||||||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
首頁 上一頁 1 下一頁 末頁 (頁 | |
[Canadian Journal of Diabetes] 的評論 | 撰寫評論 |
作者: Calvin Veblen 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-10-20 21:47:34 評論於 Is the workload required for the paper large? Can only WB+pcr be submitted?(0) 讚! | Calvin Veblen |
作者: 泄矢泰和 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-10-19 17:17:49 評論於 Review Speed: 3.0 Experience Sharing: Just received a paper, sharing the submission experience, hoping it will be helpful to everyone. 5.17 submitted to journal. 5.20 under review. 8.9 major revision. 9.9 revision submitted to journal. 10.7 minor revision. 10.19 accepted(0) 讚! | 泄矢泰和 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 19:10:41 評論於 Concise and clear titles directly reflect the core content of the article, often attracting attention and giving a comfortable feeling. At the same time, the title of SCI paper is beautiful and inspiring readers' interest(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 12:41:54 評論於 I am grateful for all the love and support you have given me throughout the years. Your kindness has been a guiding light in my life, and I am truly blessed to have you by my side(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 北国博达 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-27 14:09:12 評論於 What kind of topics can impress the reviewers?(0) 讚! | 北国博达 |
作者: 北国博达 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-26 23:29:04 評論於 What kind of titles do reviewers generally prefer?(0) 讚! | 北国博达 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-07-18 17:58:02 評論於 It's annoying. I had over 2 points for my publication last year, but this year it's only over 1 point. Will it have to decrease next year? Who would want to invest in it?!(0) 讚! | 凌霄高洁 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-07-18 09:53:32 評論於 It's too harsh! After such a big drop, who dares to invest in the future??(0) 讚! | 凌霄高洁 |
首頁 上一頁 1 下一頁 末頁 (頁 |
Contact us